Delta Global Management LP Has $418,000 Stock Holdings in Penumbra, Inc. $PEN

Delta Global Management LP lessened its stake in Penumbra, Inc. (NYSE:PEN) by 83.0% during the 4th quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 1,345 shares of the company’s stock after selling 6,551 shares during the quarter. Delta Global Management LP’s holdings in Penumbra were worth $418,000 at the end of the most recent reporting period.

Several other large investors have also recently added to or reduced their stakes in PEN. Vanguard Personalized Indexing Management LLC boosted its position in Penumbra by 5.4% during the fourth quarter. Vanguard Personalized Indexing Management LLC now owns 4,815 shares of the company’s stock valued at $1,497,000 after purchasing an additional 248 shares during the last quarter. MML Investors Services LLC raised its position in Penumbra by 13.2% during the fourth quarter. MML Investors Services LLC now owns 1,563 shares of the company’s stock valued at $486,000 after acquiring an additional 182 shares in the last quarter. Motiv8 Investments LLC bought a new position in Penumbra during the fourth quarter valued at approximately $27,000. Landscape Capital Management L.L.C. bought a new position in Penumbra during the fourth quarter valued at approximately $1,993,000. Finally, Entropy Technologies LP acquired a new position in Penumbra during the fourth quarter worth $479,000. Institutional investors and hedge funds own 88.88% of the company’s stock.

Penumbra Stock Performance

NYSE PEN opened at $318.38 on Wednesday. The company has a debt-to-equity ratio of 0.01, a current ratio of 6.02 and a quick ratio of 3.95. The firm has a market capitalization of $12.52 billion, a price-to-earnings ratio of 73.36, a P/E/G ratio of 1.95 and a beta of 0.71. The company’s fifty day moving average is $325.20 and its two-hundred day moving average is $327.83. Penumbra, Inc. has a 52-week low of $221.26 and a 52-week high of $362.41.

Penumbra (NYSE:PEN) last posted its quarterly earnings results on Wednesday, May 6th. The company reported $0.82 earnings per share (EPS) for the quarter, missing the consensus estimate of $1.06 by ($0.24). The company had revenue of $374.76 million during the quarter, compared to analyst estimates of $370.47 million. Penumbra had a return on equity of 10.87% and a net margin of 11.76%.The business’s revenue for the quarter was up 15.6% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.83 earnings per share. Equities research analysts forecast that Penumbra, Inc. will post 5.08 EPS for the current year.

Insider Activity at Penumbra

In other Penumbra news, Director Harpreet Grewal sold 100 shares of the firm’s stock in a transaction that occurred on Thursday, April 2nd. The stock was sold at an average price of $328.22, for a total value of $32,822.00. Following the completion of the sale, the director owned 8,719 shares in the company, valued at approximately $2,861,750.18. This trade represents a 1.13% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 2.90% of the company’s stock.

Wall Street Analyst Weigh In

PEN has been the topic of several analyst reports. Royal Bank Of Canada reissued a “sector perform” rating and set a $374.00 target price on shares of Penumbra in a research report on Thursday, June 11th. Evercore reaffirmed an “outperform” rating and set a $335.00 target price on shares of Penumbra in a research report on Thursday, May 7th. UBS Group reaffirmed a “neutral” rating and set a $374.00 target price on shares of Penumbra in a research report on Thursday, February 26th. Wall Street Zen raised Penumbra to a “hold” rating in a research report on Saturday, May 9th. Finally, Citigroup decreased their target price on Penumbra from $374.00 to $350.00 and set a “neutral” rating for the company in a research report on Thursday, May 7th. Three investment analysts have rated the stock with a Buy rating and fourteen have assigned a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Hold” and an average price target of $361.33.

About Penumbra

Penumbra, Inc is a global healthcare company specializing in the development and manufacture of innovative medical devices that address neurovascular and peripheral vascular conditions. The company focuses on products designed to improve patient outcomes in acute ischemic stroke, aneurysm treatment and peripheral thrombectomy. Penumbra’s technologies are used by interventional neuroradiologists, neurosurgeons and interventional cardiologists in hospitals and clinics around the world.

At the core of Penumbra’s portfolio is its mechanical thrombectomy platform, which includes aspiration catheters and accessory devices engineered to remove blood clots in acute stroke cases.